[1]斯晓燕,张力.西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J].第三军医大学学报,2012,34(20):2063-2066.
 Si Xiaoyan,Zhang Li.Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(20):2063-2066.
点击复制

西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
34卷
期数:
2012年第20期
页码:
2063-2066
栏目:
论著
出版日期:
2012-10-30

文章信息/Info

Title:
Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer
作者:
斯晓燕张力
中国医学科学院中国协和医科大学北京协和医院呼吸内科
Author(s):
Si Xiaoyan Zhang Li
Department of Respiratory Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, 100730, China
关键词:
西妥昔单抗非小细胞肺癌化疗
Keywords:
cetuximabnon-small cell lung cancerchemotherapy
分类号:
R730.5;R734.2;R979.1
文献标志码:
A
摘要:
目的      研究西妥昔单抗联合化疗一线治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效。      方法      回顾性分析北京协和医院呼吸内科2008年11月至2012年4月使用西妥昔单抗联合化疗的20例非小细胞肺癌患者的临床资料,进行疗效和安全性评估。所有患者签署了知情同意书,并同意提供临床资料。      结果      截至分析之日尚有8例患者仍存活,最长1例用药后存活了39.8个月。客观反应率(ORR)、疾病控制率(DCR)、无进展生存(PFS)和总生存(OS)时间分别为50.0%、70.0%、8.6个月和10.9个月。常见的毒副反应包括皮肤毒性(15例,75.0%)、谷丙转氨酶升高(3例,15.0%)、血液系统毒性(2例,10.0%)、过敏(1例,5.0%)和发热(1例,5.0%)。      结论      NSCLC患者使用西妥昔单抗联合化疗作为一线治疗疗效好,严重的毒副反应发生率低且可以控制,但尚需要寻找合适的预测性标记物来筛选治疗的受益人群。
Abstract:
Objective      To evaluate the safety and efficacy of cetuximab combined with chemotherapy as first line therapy in patients with non-small cell lung cancer (NSCLC).       Methods      A retrospective analysis of clinical data was conducted in 20 patients who were given cetuximab combined with chemotherapy as first line therapy in our department between November 2008 and April 2012. All patients signed the informed consent, and consented to offer clinical information.       Results      Eight patients were alive up to the time of our analysis, and the longest survival was 39.8 months. The objective response rate (ORR), disease control rate (DCR), median progression free survival (PFS), and estimated least median overall survival (OS) were 50.0%, 70.0%, 8.6 months and 10.9 months, respectively. The common adverse events included skin toxicity (15, 75.0%), alanine aminotransferase elevation (3, 15.0%), hematological toxicity (2, 10.0%), allergy (1, 5.0%) and fever (1, 5.0%).       Conclusion      Cetuximab combined with chemotherapy as first line therapy for patients with NSCLC has promising ORR, DCR, and PFS. Serious adverse events are of low incidence and quite controllable. We should search predictive factors for selecting appropriate patients.

参考文献/References:

斯晓燕, 张力. 西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J]. 第三军医大学学报,2012,34(20):2063-2066.

相似文献/References:

[1]蒋娟,易亭伍,张瑜,等.非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体基因异质性的研究[J].第三军医大学学报,2012,34(20):2039.
 Jiang Juan,Yi Tingwu,Zhang Yu,et al.Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(20):2039.
[2]杨庆羚,刘翩,王斌,等.EGFR-TKIs治疗晚期非小细胞肺癌并发间质性肺炎4例报告并文献复习[J].第三军医大学学报,2012,34(20):2060.
 Yang Qingling,Liu Pian,Wang Bin,et al.Interstitial pneumonia in EGFR-TKIs-treated non-small-cell lung cancer: report of 4 cases and review of the literature[J].J Third Mil Med Univ,2012,34(20):2060.
[3]罗虎,罗丹,宫亮,等.联合CIK细胞与化疗对比单纯化疗治疗中晚期非小细胞肺癌的Meta分析[J].第三军医大学学报,2012,34(20):2119.
[4]张瑞萍,吴继华,黄英武,等.循环肿瘤细胞检测指导老年非小细胞肺癌个体化治疗1例[J].第三军医大学学报,2012,34(22):2248.
[5]闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913.
 YAN Xia,CAO Guan-min,WANG Dao-xin.Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients[J].J Third Mil Med Univ,2007,29(20):1913.
[6]闵发胜,陈正堂.人非小细胞肺癌与外周血淋巴细胞表达LRP的相关性研究[J].第三军医大学学报,2007,29(17):1699.
 MIN Fa-sheng,CHEN Zheng-tang.Correlation between expression of lung resistance-related protein in non-small cell lung cancer and that in peripheral blood lymphocytes[J].J Third Mil Med Univ,2007,29(20):1699.
[7]高娟,饶进军,吴少瑜,等.丁酸钠与顺铂联用对非小细胞性肺癌细胞生长的抑制作用[J].第三军医大学学报,2007,29(11):1066.
 GAO Juan,RAO Jin-jun,WU Shao-yu,et al.Combination of sodium butyrate and cisplatin has antiproliferative effects on non-small lung cancer cell line[J].J Third Mil Med Univ,2007,29(20):1066.
[8]郑顺利,杨庆生,马小红.非小细胞肺癌患者纵隔淋巴结和外周血中MUC1基因的检测及意义[J].第三军医大学学报,2006,28(24):2472.
[9]张云嵩,范士志,王东,等.APE1在非小细胞肺癌中的表达特点及其与预后的关系[J].第三军医大学学报,2007,29(09):776.
 ZHANG Yun-song,FAN Shi-zhi,WANG Dong,et al.APE1 expression and its correlation with prognosis in non-small cell lung cancer[J].J Third Mil Med Univ,2007,29(20):776.
[10]徐小杰,梅同华.非小细胞肺癌组织中KAI1/CD82基因表达及意义[J].第三军医大学学报,2006,28(13):1443.

更新日期/Last Update: 2012-10-18